Serum Analysis of Coagulation Factors in IPF and NSIP

被引:0
作者
E. Bargagli
C. Madioni
N. Bianchi
R. M. Refini
R. Cappelli
P. Rottoli
机构
[1] Siena University,Respiratory Diseases Section, Department of Clinical Medicine and Immunological Sciences
[2] Siena University,Cardiovascular and Geriatric Section, Department of Clinical Medicine and Immunological Science
来源
Inflammation | 2014年 / 37卷
关键词
coagulation system; idiopathic pulmonary fibrosis; acute exacerbation; nonspecific pulmonary fibrosis;
D O I
暂无
中图分类号
学科分类号
摘要
Recent literature and our previous proteomic findings prompted us to study the coagulation system in idiopathic pulmonary fibrosis (IPF), the pathogenesis of which remains unclear. The aim of this study was to compare coagulation factors in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia (NSIP) patients and healthy controls. Thirty-three IPF patients (23 acute exacerbation and 10 stable IPF patients), 7 NSIP patients, and 44 controls were enrolled. Concentrations of D-dimer, homocysteine, functional protein C, protein C antigen, free and total protein S antigen and activity, fibrinogen and factor VIIIc were analyzed in serum of patients and controls. The lupus anticoagulant (LAC) test was also performed. Factor VIIIc levels were significantly higher in acute exacerbation IPF patients than controls (p = 0.0001) and in stable IPF patients than controls (p = 0.002). Factor VIIIc levels were higher and PT levels were lower in acute exacerbation IPF patients who died after exacerbation than in patients who survived (p = 0.04 and p = 0.003, respectively). D-dimer, fibrinogen, and homocysteine levels were also significantly higher in IPF patients than controls (p < 0.01). Protein C activity was increased in acute exacerbation IPF patients than controls (p = 0.005). The LAC test was positive in seven IPF patients and negative in controls. Procoagulant status was demonstrated in IPF patients (mainly in acute exacerbation/IPF) than controls and NSIP patients, probably due to endothelial activation and microvascular injury. These preliminary results are of interest because of their potential implications in the pathogenesis and treatment of this disease.
引用
收藏
页码:10 / 16
页数:6
相关论文
共 82 条
  • [1] Raghu G(2011)AN official ATS/ERS/JRS/ALAT statement: IPF evidence-based guidelines for diagnosis and treatment American Journal of Respiratory and Critical Care Medicine 183 788-824
  • [2] Collard HR(2008)Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling European Respiratory Review 17 130-137
  • [3] Egan JJ(2007)Cellular origin of pro-coagulant and antifibrinolytic factors in bleomycin-injured lungs European Respiratory Journal 29 1105-1114
  • [4] Chambers RC(2008)Procoagulant signalling mechanisms in lung inflammation and fibrosis: new opportunities for pharmacological intervention? British Journal of Pharmacology 153 S367-S378
  • [5] Wygrecka M(2008)Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases Thrombosis and Haemostasis 99 494-501
  • [6] Markart P(2012)The roles of thrombin and protease-activated receptors in inflammation Seminars in Immunopathology 34 63-72
  • [7] Ruppert C(2005)Anticoagulant therapy for idiopathic pulmonary fibrosis Chest 128 1475-1482
  • [8] Chambers RC(2006)Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies Human Immunology 67 284-297
  • [9] Wygrecka M(2009)Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury The Journal of Clinical Investigation 119 2550-2563
  • [10] Jablonska E(2003)The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis American Journal of Clinical Pathology 203 556-567